IMUX Share Price | Immunic, Inc. Stock Analysis & Recommendation

Q: How big is Immunic, Inc.?

Market Cap: As of Jun 18, Immunic, Inc. has a market capitalization of 73.54 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Immunic, Inc. reported net sales of 0.00 million and a net profit of -96.40 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 18.43 million, while total assets were reported at 40.87 million.

Q: What does Immunic, Inc. do?

Overview:Immunic, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for chronic inflammatory and autoimmune diseases within the Pharmaceuticals & Biotechnology industry.Financial Snapshot:Most recent Net Profit: -25 Million (Quarterly Results - Mar 2025)Market cap: USD 73.54 Million (Micro Cap)Key Metrics:Debt Equity: 2.56Return on Equity: 1,823.26%Price to Book: -13.91Contact Details:Address: Am Klopferspitz 19, PLANEGG CA: 82152Tel: ['49 89 250079460', '49 892 08047709']Fax: 1 302 6555049

Q: Is Immunic, Inc. technically bullish or bearish?

As of 17 July 2025, the technical trend for Immunic, Inc. has changed from bearish to mildly bearish. The weekly MACD is bearish, while the monthly MACD shows a mildly bullish stance. The Bollinger Bands indicate a mildly bearish trend for both weekly and monthly periods. Daily moving averages are bearish, and the KST is mildly bullish on a weekly basis but bearish monthly. Dow Theory supports a mildly bullish outlook for both weekly and monthly periods, while the OBV is mildly bearish.In terms of performance, Immunic has significantly underperformed compared to the S&P 500 across all periods, with a 1-year return of -53.07% versus the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, reflecting a lack of strong bullish signals despite some mixed indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.01 M

Shareholding (Dec 2025)

FII

2.74%

Held by 21 FIIs

DII

74.2%

Held by 28 DIIs

Promoter

1.81%

How big is Immunic, Inc.?

22-Jun-2025

As of Jun 18, Immunic, Inc. has a market capitalization of 73.54 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -96.40 million over the latest four quarters. Shareholder's funds are 18.43 million, and total assets are 40.87 million as of Dec 24.

View full answer

What does Immunic, Inc. do?

22-Jun-2025

Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral therapies for chronic inflammatory and autoimmune diseases. As of March 2025, it has a market cap of $73.54 million and reported a net profit of -$25 million.

View full answer

Who are in the management team of Immunic, Inc.?

22-Jun-2025

As of March 2022, the management team of Immunic, Inc. includes Dr. Daniel Vitt as President and CEO, along with independent directors Ms. Tamar Howson, Dr. Jorg Neermann, Dr. Vincent Ossipow, Mr. Barclay Phillips, and Mr. Jan Van den Bossche.

View full answer

Is Immunic, Inc. technically bullish or bearish?

20-Sep-2025

As of July 17, 2025, Immunic, Inc. shows a mildly bearish technical trend with mixed indicators, underperforming the S&P 500 significantly over the past year.

View full answer

Compare Immunic, Inc. with Similar Stocks

Veru, Inc.Homology Medicines, Inc.Eyenovia, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 151 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-3.28

Return on Equity

-981.49%

Price to Book

14.41

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-19 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

94.14%

6 Months

30.95%

1 Year

-2.65%

2 Years

-16.03%

3 Years

-33.33%

4 Years

-90.79%

5 Years

-92.64%

Immunic, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-185.46%

EBIT to Interest (avg)

-74.29

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

2.56

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

64.42%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

14.41

EV to EBIT

-1.11

EV to EBITDA

-1.11

EV to Capital Employed

-4.88

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-981.49%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 9 Schemes (21.24%)

Foreign Institutions

Held by 21 Foreign Institutions (2.74%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 23.41% vs -16.67% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.30",
          "val2": "-25.60",
          "chgp": "8.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-19.30",
          "val2": "-25.20",
          "chgp": "23.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 3.28% vs -7.37% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-103.10",
          "val2": "-97.90",
          "chgp": "-5.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-4.80",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-97.20",
          "val2": "-100.50",
          "chgp": "3.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-23.30

-25.60

8.98%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-19.30

-25.20

23.41%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 23.41% vs -16.67% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-103.10

-97.90

-5.31%

Interest

0.00

Exceptional Items

0.00

-4.80

100.00%

Consolidate Net Profit

-97.20

-100.50

3.28%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 3.28% vs -7.37% in Dec 2024

All Annual Results

Company CV

About Immunic, Inc.

Immunic, Inc.

Pharmaceuticals & Biotechnology

Immunic, Inc., formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.

Company Coordinates

Company Details

Am Klopferspitz 19 , PLANEGG CA : 82152

Tel: 49 89 25007946049 892 08047709

Registrar Details